EMDC

The Beginner’s Guide to Pharma Social Media TONS of resources here. Including a response to the oft-asked “What about adverse events?” question.

Eye on FDA: What We Didn’t Hear at the FDA Part 15 Meeting on Social Media We heard from far too few pharma companies, and far too many bloggers. What was missing? What anyone should be doing in the meantime, what’s the process going forward, and what (if anything) is going on in Europe.

Rich Meyer says pharma marketers don’t even know what to do with the web traffic data they already have much less how to integrate social media into the mix, which is ironic considering how much research goes into pharma industry decision-making.

AdAge: FDA to Hold Public Hearings on Big Pharma’s Social-Media Use The U.S. Food and Drug Administration will hold a two-day public hearing in November on how pharmaceutical companies use the web and social-media tools to market their products, the first step in a long overdue process that will finally establish guidelines for how drug [...]

“Use of internet-based social media such as Facebook and Twitter can pose compliance risks for drug companies, experts agree.” — I’ll say this: Any time anyone who is employed by a drug (or device, or biotech) company opens their mouth, it’s a compliance risk. Regulated companies can and should use social media channels to market themselves instead of their products.